US 7,572,802 B2
7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine
Craig D. Boyle, Branchburg, N.J. (US); Samuel Chackalamannil, Califon, N.J. (US); Unmesh Shah, Green Brook, N.J. (US); and Jean E. Lachowicz, Berkeley Heights, N.J. (US)
Assigned to Schering Corporation, Kenilworth, N.J. (US)
Filed on Sep. 21, 2006, as Appl. No. 11/525,065.
Claims priority of provisional application 60/720027, filed on Sep. 23, 2005.
Prior Publication US 2007/0072867 A1, Mar. 29, 2007
Int. Cl. A61K 31/505 (2006.01); C07D 239/00 (2006.01); C07D 471/00 (2006.01); C07D 487/00 (2006.01); C07D 491/00 (2006.01)
U.S. Cl. 514—267  [544/251] 15 Claims
 
1. A method of treating Parkinson's Disease, Extra-Pyramidal Syndrome, dystonia, akathisia, pseudoparkinsonism, tardive dyskinesia, restless legs syndrome, essential tremor, Huntington's Disease, attention deficit hyperactivity disorder, Alzheimer's Disease, negative symptoms of schizophrenia, depression, stroke or psychoses with a compound of the formula

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof.